Blood 2021

As for many immunocompromised patients, the fear of contracting COVID-19 during the pandemic has contributed to a high psychological burden for patients with haematological malignancies. Speaking at the Blood 2021 Congress, Dr Nienke Zomerdijk said that fear and concern about their...

As for many immunocompromised patients, the fear of contracting COVID-19 during the pandemic has contributed to a high psychological burden...

Direct oral anticoagulants have transformed care in the last 10-15 years but there are still unmet needs in anticoagulant therapy, an international speaker told the Blood 2021 meeting. Presenting the Barry Firkin Oration, Professor John Eikelboom said contraindications, limited effectiveness in...

Direct oral anticoagulants have transformed care in the last 10-15 years but there are still unmet needs in anticoagulant therapy,...

The selective bruton's tyrosine kinase (BTK) inhibitor zanubrutinib has shown promise as a novel, more effective and tolerable therapy for patients with relapsed/refractory marginal zone lymphoma (MZL). The phase 2, single arm, open label MAGNOLIA study, presented at Blood 2021, comprised...

The selective bruton's tyrosine kinase (BTK) inhibitor zanubrutinib has shown promise as a novel, more effective and tolerable therapy for...